Tag Archives: diabetes innovation

Diabetes care has advanced dramatically over the past decade. While therapies such as GLP-1 receptor agonists and SGLT2 inhibitors have transformed glucose management and cardiovascular outcomes, many patients continue to develop long-term complications. Could an older therapeutic target finally provide the missing piece? Interest in aldose reductase inhibitors for diabetes …

For more than a century, insulin therapy has remained the cornerstone of treatment for type 1 diabetes. While continuous glucose monitors, insulin pumps, and automated insulin delivery systems have dramatically improved diabetes management, they still do not replace the body’s natural ability to regulate blood sugar. As a result, researchers …

Finding the right diabetes medication often involves trial and error. One patient may respond well to a GLP-1 receptor agonist, while another sees little benefit from the same treatment. As a result, clinicians frequently adjust medications before finding the most effective option. What if doctors could test a patient’s response …

Every new diabetes medication must prove it is both safe and effective before reaching patients. Traditionally, that process depends on large clinical trials that require thousands of volunteers, years of follow-up, and significant financial investment. However, what if researchers could reduce the number of participants while still producing reliable scientific …

For millions of people living with diabetes, checking blood sugar remains a daily routine that often involves fingersticks or wearing a continuous glucose monitor (CGM) with a tiny sensor inserted beneath the skin. Although CGMs have dramatically improved diabetes management, many people still hope for a truly needle-free alternative. That …

Diabetes research has advanced rapidly over the past two decades, leading to groundbreaking medications such as GLP-1 receptor agonists, SGLT2 inhibitors, and dual incretin therapies. However, one challenge remains constant: developing new treatments through traditional clinical trials is often expensive, time-consuming, and inflexible. Could there be a better way to …

For decades, glucagon has been viewed as insulin’s opposite. While insulin lowers blood glucose, glucagon raises it by signaling the liver to release stored sugar into the bloodstream. Because of this, glucagon has traditionally been considered a hormone to suppress in people living with type 2 diabetes. However, modern research …

For decades, diabetes treatment has centered on medications, insulin therapy, lifestyle changes, and increasingly sophisticated medical devices. But what if a completely different approach could help regulate blood sugar without adding another drug? That intriguing question is driving research into hepatic neuromodulation for diabetes, a promising field that uses focused …

For more than a century, insulin has saved millions of lives. Yet despite remarkable advances in diabetes technology, one major challenge remains: preventing hypoglycemia while maintaining excellent glucose control. That is why researchers are developing glucose-responsive insulin, often called “smart” insulin. Instead of delivering a fixed amount of insulin regardless …

For many people living with diabetes, gaining access to an automated insulin delivery (AID) system can be life-changing. These technologies help improve glycemic outcomes, reduce hypoglycemia risk, and ease the daily burden of diabetes management. Yet despite their proven benefits, many patients continue to face lengthy delays before gaining access. …